Senti Bio and Bluerock ink Regmed collaboration
Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
Pieris in $1.4bn deal with Roche
German-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
|
|
|
||
Associations call for acceleration of ATMP trials in Europe
Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.
COVID-19 med APN01 selected to be tested in ACTIV study
APEIRON Biologics recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.
Hummingbird Bioscience raises $125m in Series C financing
Danish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
BD installs production hub in Zaraogza
BD will build a 165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches 300m funding
German government has launched a 300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
Recombinant silk producer AMSilk raises 29m
AMSilk GmbH has closed a Series C financing at 29m to accelerate and expand commercialisation of its microbially produced silk fibres.
SARS-CoV-2-antibodies may promote severe COVID-19
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.